T estosterone therapy is prescribed for millions of men each year, and the number is increasing rapidly. Prescription sales of testosterone increased by 500% in the United States between 1993 and 2000. 1 Most tes tosterone prescriptions are written to treat non specific symptoms, such as fatigue or sexual dys function, when accompanied by testosterone levels below the laboratory reference range. Cur rently, testosterone levels that are at least 2 SD below the mean value for healthy young adults are classified as low. 1,2 Although convenient, this classification fails to consider the physiological consequences of specific testosterone levels.
More than 80% of circulating estradiol in men is derived from the aromatization of testos terone. 3 Thus, as serum testosterone levels de cline, there is a concomitant decline in serum estradiol levels. 4, 5 Nevertheless, the consequenc es of male hypogonadism are routinely attribut ed solely to androgen deficiency; the potential role of the concomitant decline in estrogens is typically ignored. It has become clear, however, that estrogen deficiency may be important in the pathogenesis of some consequences of male hypogonadism, such as bone loss. [6] [7] [8] The poten tial role of estrogen deficiency in the pathogen esis of other consequences of hypogonadism, such as alterations in body composition or sex ual function, is largely unknown. Information on the role of estrogens in male hypogonadism may help identify men at risk for specific mani festations of the condition and may provide a rationale for novel approaches to its manage ment. We sought to determine the relative de gree of testosterone deficiency, estradiol defi ciency, or both at which undesirable changes in body composition, strength, and sexual function begin to occur and whether those changes are due to androgen deficiency, estrogen deficiency, or both.
ME THODS

Study Participants
We recruited two cohorts of men who were 20 to 50 years of age and healthy. All the men had nor mal serum testosterone levels. Details of the eli gibility criteria and study completion are provid ed in the Supplementary Appendix, available with the full text of this article at NEJM.org.
Study Design and Protocol
All participants received goserelin acetate (Zola dex, AstraZeneca), at a dose of 3.6 mg subcutane ously at weeks 0, 4, 8, and 12, to suppress endog enous gonadal steroids. Participants were then randomly assigned to receive 0 g (placebo), 1.25 g, 2.5 g, 5 g, or 10 g of a topical 1% testosterone gel (AndroGel, Abbott Laboratories) daily for 16 weeks. Participants in cohort 2 also received anastrozole (Arimidex, AstraZeneca) at a dose of 1 mg daily to block the aromatization of testosterone to es trogen. Participants were unaware of the study group assignments.
Participants were seen every 4 weeks. At each visit, fasting blood samples were obtained to measure gonadal steroid levels, and question naires were administered to assess physical function, health status, vitality, and sexual func tion. At baseline and week 16, body fat and lean mass were assessed by means of dualenergy xray absorptiometry (DXA); subcutaneous and intraabdominalfat areas and thighmuscle area were measured by means of computed tomogra phy (CT); and lowerextremity strength was de termined by means of a leg press. Data on bone homeostasis (boneturnover markers and bone mineral density), risk factors for cardiovascular disease (blood pressure, lipids, and insulin sensi tivity), and levels of leptin and prostatespecific antigen were also collected but are not included in the present report.
The study was approved by the institutional review board of Partners HealthCare. All par ticipants provided written informed consent. All authors vouch for the completeness and accuracy of the data and analyses and the fidelity of the study to the protocol (available at NEJM.org). All authors made the decision to submit the manu script for publication. Abbott Laboratories pro vided partial financial support and supplied the testosterone gel at no charge but had no role in the study design, data analysis, data interpreta tion, or manuscript preparation. AstraZeneca provided Zoladex and Arimidex at no cost but had no role in the study design, data analysis, data interpretation, or manuscript preparation.
analyzer (ADVIA Centaur XP, Siemens). The as say sensitivity was 20 ng per deciliter. The total testosterone level was remeasured by means of liquid chromatography-tandem mass spectrosco py at all time points in serum samples obtained from five randomly selected men in each of the five dose groups in cohort 1. 9 The correlation be tween the testosterone assays was 0.93, and the assays had very similar results (T radioimmunoassay = 0.98T mass spectroscopy + 21 ng per deciliter). The se rum level of estradiol was measured with the use of liquid chromatography-tandem mass spectros copy, with a threshold for detection of 1.25 pg per milliliter. 9
Outcomes and Assessments
The primary outcome variables were changes in the DXAbased measures of body fat and lean mass. The percentage of body fat and the total body lean mass were determined by means of DXA (QDR 4500A, Hologic). 10 Subcutaneous and intraabdominalfat areas were determined by means of CT at the L4 vertebral level with a LightSpeed Pro 16 scanner (General Electric Medical Systems). 11 Crosssectional thighmus cle area was determined at the midpoint of the femur. 12 Lowerextremity strength was assessed as the maximum weight lifted for one repetition with the use of a leg press (Air 300, Keiser). 13 Sexual function, physical function, vitality, and overall health status were assessed at each visit with the use of a selfadministered question naire on healthrelated quality of life that was previously validated in patients with prostate cancer who were undergoing androgendepriva tion therapy. 14 Sexual function was divided into domains of sexual desire and erectile function.
The primary analysis was a modified inten tiontotreat analysis. Because we were assessing changes in outcome variables, participants who completed only the baseline visit could not be included in any longitudinal analyses. Because changes in body composition are unlikely to occur within the first several weeks of hormonal ma nipulation, the protocol required that participants complete the first three visits (through week 8) to avoid exposing participants to additional radia tion from repeat bodycomposition scans when it appeared unlikely that the results would be infor mative. In addition, the protocol required that participants miss no more than 20% of their study medication doses to be included in the analyses. Participants who discontinued the study medication after week 8 but before week 16 were asked to undergo followup bodycomposition and strength assessments at their final visit.
Statistical Analysis
The study was designed to have 80% power at an alpha level of 0.025, with the use of a oneway analysis of variance to detect mean changes from baseline to 16 weeks of at least 0.3 times the common standard deviation for bodycomposi tion measures on DXA and subcutaneousfat area and thighmuscle area on CT. These calculations were based on a sample of 40 participants per dose group, with the assumption that 80% of par ticipants would have data that could be assessed.
To determine the testosterone dose needed to maintain body composition, strength, and sexual function, we compared changes in each outcome among dose groups with the use of Duncan's multiplerange test. To control further for type I error, we adopted a significance level of 0.025, using the Bonferroni method to adjust for the two primary outcomes. Our primary analysis focused on comparisons of the group receiving the 5g dose with the other dose groups, because this dose produced testosterone levels that were similar to baseline levels.
To determine whether the changes in each outcome were related to testosterone, estradiol, or both, we used the following approaches. To assess testosteronerelated effects, we compared changes in each outcome among all dose groups in cohort 2 with the use of Duncan's multiple range test. Because anastrozole suppresses es tradiol production dramatically, differences be tween groups within cohort 2 should reflect the effect of testosterone on each outcome. To as sess estradiolrelated effects, we used general linear model-based tests with 1 degree of free dom in which the effects were cohort (cohort 1 or cohort 2), the groupspecific testosterone dose, and the cohort-testosterone dose interaction. The interaction compares the slopes of regres sion of the testosterone dose with the outcome values in cohort 1 and cohort 2. The effects of estradiol on each outcome were also inferred with the use of independent ttests to compare the mean change in each outcome for all groups that received testosterone (1.25 g, 2. 10 g daily) in cohort 1 with the mean change in all groups that received testosterone plus an aromatase inhibitor in cohort 2. Because testos terone doses were identical in the two cohorts and estradiol synthesis was selectively inhibited in cohort 2, differences in outcomes between cohorts with the use of this approach should also reflect the effects of estradiol. All reported P values are twosided. P values of less than 0.025 were considered to indicate statistical significance, with the exception that for interaction tests, P values of less than 0.05 were considered to indicate statistical signifi cance. Unless otherwise noted, data are pre sented as means ±SD.
R E SULT S
Baseline Characteristics and Study Completion
We enrolled 198 men in cohort 1 (Fig. 1A ) and 202 men in cohort 2 (Fig. 1B ). There were no significant differences in baseline testosterone levels among dose groups or between cohorts (Table 1) . Ten men in cohort 1 and 27 in cohort 2 discontinued the study before week 8 and were included in analyses of baseline data only. We conducted a modified intentiontotreat analy sis of the remaining data. In cohort 1, a total of 24 men discontinued participation between weeks 8 and 16, of whom 16 underwent followup bodycomposition and strength testing. Four ad ditional participants were later excluded for proto col violations. In cohort 2, a total of 17 men dis continued participation between weeks 8 and 16, of whom 13 underwent followup bodycomposi tion and strength testing. One participant in co hort 2 was excluded for a protocol violation. Paired DXA, CT, or strength tests could not be completed in an additional 3, 5, and 10 men, re spectively, in cohort 1 and in 1, 1, and 12 men, respectively, in cohort 2. Thus, the respective numbers of participants included in the analy ses of sexual desire, body composition as mea sured by DXA, body composition as measured by CT, and strength were 184, 173, 171, and 166 for cohort 1 and 174, 169, 169, and 158 for cohort 2.
Hormone Levels
In men receiving goserelin acetate and 0 g (pla cebo), 1.25 g, 2.5 g, 5 g, or 10 g of testosterone gel daily (cohort 1), the mean testosterone levels were 44±13 ng per deciliter, 191±78 ng per deci liter, 337±173 ng per deciliter, 470±201 ng per deciliter, and 805±355 ng per deciliter, respectively ( Fig. 2A) . The corresponding mean estradiol levels were 3.6±1.4 pg per milliliter, 7.9±2.9 pg per mil liliter, 11.9±5.7 pg per milliliter, 18.2±10.2 pg per milliliter, and 33.3±15.3 pg per milliliter (Fig. 2B) . In men who also received anastrozole (cohort 2), the corresponding mean testosterone levels were 41±13 ng per deciliter, 231±171 ng per deciliter, 367±248 ng per deciliter, 485±240 ng per deci liter, and 924±521 ng per deciliter ( Fig. 2A) , and the corresponding mean estradiol levels were 1.0±0.4 pg per milliliter, 1.2±0.4 pg per milliliter, 2.0±2.3 pg per milliliter, 2.1±1.9 pg per millili ter, and 2.8±1.8 pg per milliliter (Fig. 2B) .
Effects of Testosterone without Aromatase Inhibition on Body Composition
In cohort 1, the percentage of body fat increased significantly in men who received 0 g, 1.25 g, or 2.5 g of testosterone daily, as compared with men who received 5 g daily, and it decreased sig nificantly in men who received 10 g of testoster one daily, as compared with each of the other groups (Fig. 3A) . Lean mass decreased signifi cantly in men who received placebo or 1.25 g of testosterone daily, as compared with men who received 2.5 g, 5 g, or 10 g of testosterone daily (Fig. 3B ). Subcutaneousfat area increased by a factor of 2 to 3 in men receiving 0 g, 1.25 g, or 2.5 g of testosterone daily, as compared with men receiving 5 g or 10 g daily, though only the comparisons with the 10g dose group were sig nificant ( Fig 3C) . Intraabdominalfat area did not change significantly in any group (Fig. 3D ). Participants were recruited by sending letters to men in the local area who were identified with the use of commercially available mailing lists or by advertising in newspapers or on the Internet. A computerized program was used to randomly assign participants in permuted blocks. The block sizes were also randomly determined. Participants in cohort 1 (Panel A) were assigned to receive goserelin acetate plus placebo (group 1 Thighmuscle area decreased significantly in men who received placebo or 1.25 g of testoster one daily, as compared with men who received 5 g of testosterone daily, and it increased signifi cantly in men who received 10 g of testosterone daily, as compared with all the other groups (Fig.  3E) . Legpress strength decreased significantly in men who received placebo, as compared with men receiving 2.5 g, 5 g, or 10 g of testosterone daily (Fig. 3F) .
Effects of Testosterone with Aromatase Inhibition on Body Composition
In cohort 2, the percentage of body fat increased in all groups when the aromatization of testos terone to estradiol was inhibited. The magni tudes of these increases were similar with doses of 0 g, 1.25 g, 2.5 g, and 5 g of testosterone daily, a finding that suggests a predominantly estro genic effect (Fig. 3A) . Totalbody lean mass de creased significantly in men who received place bo, as compared with those who received 1.25 g, 2.5 g, or 10 g of testosterone daily, a finding that implies an independent effect of testosterone (Fig. 3B) . Subcutaneousfat area increased in all groups in cohort 2, though only the comparison of changes between the 1.25g and 10g dose groups was significant (Fig. 3C) . The increases in intraabdominalfat area did not differ sig nificantly among the dose groups (Fig. 3D) . Thighmuscle area decreased significantly in men who received placebo, as compared with men who received any of the four testosterone doses (Fig. 3E ). As in cohort 1, legpress strength declined significantly in men who received pla cebo, as compared with men who received the three highest testosterone doses (Fig. 3F) .
Effects of Testosterone with and without Aromatase Inhibition on Sexual Function
In cohort 1, sexual desire decreased progressively with declining testosterone doses, from 10 g to 0 g of testosterone daily, and all dose groups differed significantly from one another except for the 2.5g and 5g dose groups (Fig. 4A) . Erectile function worsened significantly in men who received pla cebo, as compared with men who received testos terone, and declined more in men who received Leg-press strength (lb) 613±152 645±171 592±127 † 701±195
1.25 g of testosterone daily than in men in the three highest dose groups (Fig. 4B) . In cohort 2, sexual desire declined signifi cantly in men who received placebo, as compared with men in the three highest dose groups, and declined more in men who received 1.25 g of testosterone daily than in men in the two high est dose groups (Fig. 4A ). Erectile function de creased more in men who received placebo than in men who received testosterone (Fig. 4B) . Re sults for other selfreported measures are avail able in the Supplementary Appendix.
Comparisons of Changes in Body Composition and Sexual Function with and without Aromatase Blockade
The cohort-testosterone dose interaction was significant for the percentage of body fat (P = 0.001), intraabdominalfat area (P = 0.021), subcutaneousfat area (P = 0.029), sexual desire (P = 0.045), and erectile function (P = 0.032); these findings indicate that estradiol exerted an inde pendent effect on these variables (Fig. 3 and 4) . In the groups that received testosterone, inhibi tion of estrogen synthesis (cohort 2), as com pared with intact estrogen synthesis (cohort 1), was associated with significant increases in the percentage of body fat (P<0.001), subcutaneous fat area (P<0.001), and intraabdominalfat area (P = 0.002) and with significant decreases in sexual desire (P<0.001) and erectile function (P = 0.022); these findings provide additional evidence of an independent effect of estradiol on these mea sures. The cohort-testosterone dose interaction was not significant for totalbody lean mass (P = 0.22), thighmuscle area (P = 0.20), or leg press strength (P = 0.91); among the men who received testosterone, there were no significant differences between cohorts in changes from baseline for totalbody lean mass (P = 0.52), thighmuscle area (P = 0.19), or legpress strength (P = 0.90).
DISCUSSION
Although the sensitivity of various androgen tar get tissues is known to vary, 15 the diagnosis of androgen deficiency is typically based on a single laboratory criterion: a testosterone level at least 2 SD below the mean value in normal young men. In this study, we found that the dose of testoster one required to prevent adverse changes in a va riety of measures varies considerably. When aro matization was intact, fat accumulation began with mild gonadal steroid deficiency (a testoster one level of approximately 300 to 350 ng per deci liter), whereas lean mass, thighmuscle area, and muscle strength were preserved until gonadal steroid deficiency was more marked (a testoster one level ≤200 ng per deciliter). Sexual desire and erectile function, the two major domains of sex ual function, showed distinct patterns of change as serum testosterone levels were reduced. The variation in tissue sensitivity to androgens could be due to polymorphisms affecting polygluta mine repeat length in the androgenreceptor gene, tissuespecific differences in androgen receptor expression or local hormone metabolism, or, as shown in the present study, variation in the roles of androgens and estrogens in the regula tion of targettissue responses. Observational studies have shown that lean mass and strength are reduced and fat mass is increased in men with low testosterone lev els. 5, 10, 11 Men with hypogonadism report less sexual activity, fewer sexual thoughts, and fewer spontaneous erections than men with normal testosterone levels. Moreover, testosterone re placement increases lean mass, decreases fat mass, and can improve sexual function in men with hypogonadism. 11, [16] [17] [18] [19] [20] [21] [22] These observations have led to the widespread belief that undesir able changes in body composition and sexual dysfunction in men with hypogonadism are due to androgen deficiency. However, because estra diol is a metabolite of testosterone, it is difficult to distinguish the effects of androgens from those of estrogens in observational studies, or even in randomized, controlled trials if aroma tizable androgens are used without the adminis tration of an aromatase inhibitor.
By administering a variety of testosterone doses with and without concomitant aromatase inhibition, we found that changes in lean mass, thighmuscle area, and legpress strength were attributable to changes in testosterone levels, whereas changes in fat measures were primarily related to changes in estradiol levels. Both an drogens and estrogens contributed to the main tenance of normal libido and erectile function. Although these results may be surprising, they are consistent with studies showing that body fat is increased in humans and male mice with null mutations of the aromatase gene or the es trogenreceptor α gene and that sexual function is markedly impaired in mice and humans with these genetic defects. [23] [24] [25] [26] Our observations may have important clinical implications. First, they provide a physiological basis for interpreting testosterone levels in young and middleaged men and identifying the adverse consequences that are most likely to oc cur at various gonadal steroid levels. Second, because increases in visceral fat reduce insulin sensitivity and are associated with diabetes and the metabolic syndrome, 27 the marked increase in intraabdominal fat with aromatase inhibition could portend an increase in cardiovascular dis ease with longterm estrogen deficiency. Finally, because lean mass, thighmuscle area, and erec tile function were reduced at a testosterone dose (1.25 g per day) that elicited a mean serum level of approximately 200 ng per deciliter, testoster one supplementation seems justified in men with testosterone levels in this range. However, some men have alterations in these functional outcomes at lower or higher testosterone levels, and other consequences of hypogonadism, such as increases in body fat and loss of sexual desire, T bars indicate standard errors. Within each cohort, bars with the same number indicate no significant difference between dose groups. For example, the change in the percentage of body fat (Panel A) did not differ significantly among the groups that received 0 g, 1.25 g, or 2.5 g of testosterone daily in cohort 1 (all labeled "1"). The change in each of those three groups differed significantly from the change in the group that received 5 g per day (labeled "2") and the change in the group that received 10 g per day (labeled "3"), and the change also differed significantly between these latter two groups. P values are for the cohort-testosterone dose interaction terms in analyses of variance comparing changes in each outcome measure between cohorts 1 and 2.
The for older men. Serum testosterone levels decline modestly as men age, such that 20% of men older than 60 years of age and 50% of men older than 80 years of age have testosterone lev els at least 2 SD below the mean level in young men. 2, 28 Aging in men is also accompanied by declines in bone mineral density, 29 lean mass, 30, 31 muscle strength, 32,33 energy, and sexual func tion 34 and by increases in fat mass 31, 35 -fea tures that collectively are reminiscent of organic hypogonadism in young men. 33 Decreases in muscle mass and strength are strong predictors of falls, fractures, and loss of the ability to live independently. 36 Thus, if young and old men have similar responses to a decline in testoster one levels, as they do to an increase in testoster one levels, 37,38 these findings suggest that some of the changes observed in aging men may be related to ageassociated changes in gonadal ste roids and may be preventable with appropriate replacement. A direct determination of the rela tionships between gonadal steroid levels and clinical measures in elderly men is needed to confirm this hypothesis.
Our finding that estrogens have a fundamen tal role in the regulation of body fat and sexual function, coupled with evidence from prior stud ies of the crucial role of estrogen in bone metabo lism, [6] [7] [8] indicates that estrogen deficiency is largely responsible for some of the key conse quences of male hypogonadism and suggests that measuring estradiol might be helpful in as sessing the risk of sexual dysfunction, bone loss, or fat accumulation in men with hypogonadism. For example, in men with serum testosterone levels of 200 to 400 ng per deciliter, sexualdesire scores decreased by 13% if estradiol levels were 10 pg per milliliter or more and by 31% if estra diol levels were below 10 pg per milliliter. Our findings also suggest that treatment with aro matizable androgens would be preferable to treat ment with nonaromatizable androgens in most men with hypogonadism.
Our study has limitations. First, to avoid clinically significant changes in healthy men, such as bone loss, the study was limited to 16 weeks. 39, 40 Because changes in body composi tion may progress over time, greater changes might have been seen at higher testosterone and estradiol levels if gonadal steroids had been sup pressed over a longer period. Second, although most circulating estradiol is derived from the aromatization of circulating testosterone, a small portion is directly secreted by the testes in normal men and may not be restored with exogenous testosterone administration. 41 Third, changes in duced by aromatase inhibition could primarily reflect the effects on local aromatase activity; therefore, circulating estradiol levels may not reflect estrogen effects reliably. Changes seen in Sexual desire (Panel A) was assessed at each visit by asking participants to rate their sex drive as compared with their sex drive before the study began (−2 indicates much less, −1 somewhat less, 0 the same, 1 somewhat more, and 2 much more). Erectile function (Panel B) was evaluated by asking each man to consider the prior month and rate the degree to which each of the following three statements most closely applied to himself: "I had difficulty becoming sexually aroused," "I had difficulty getting or maintaining an erection," and "I had difficulty reaching orgasm," with 1 indicating not at all, 2 a little, 3 some, 4 quite a bit, and 5 a great deal. For each man, the mean value at the final visit was then subtracted from the mean value at the baseline visit. T bars indicate standard errors. Within each cohort, bars with the same number indicate no significant difference between dose groups. P values are for the cohort-testosterone dose interaction terms in analyses of variance comparing changes in each outcome measure between cohorts 1 and 2.
our model of acute gonadal steroid deprivation may also differ from those seen when gonadal steroids decline gradually over a period of years. Finally, it seems likely that the relationship between declining gonadal steroid levels and the risk of adverse consequences is more accu rately represented as a continuum than as a rigid threshold above which clinical measures are normal and below which adverse changes occur. However, clinicians ultimately must de cide how to treat each patient on the basis of his individual data, of which the testosterone level is generally the principal component.
In summary, we conducted a doseranging study to determine the relative testosterone doses and associated serum levels at which body composition, strength, and sexual function ini tially decline. By examining these relationships with and without suppression of estrogen syn thesis, we found that lean mass, muscle size, and strength are regulated by androgens; fat ac cumulation is primarily a consequence of estro gen deficiency; and sexual function is regulated by both androgens and estrogens. Delineation of the degrees of hypogonadism at which undesir able consequences develop and of the relative roles of androgens and estrogens in each outcome should facilitate the development of more ratio nal approaches to the diagnosis and treatment of hypogonadism in men.
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